Valosin-containing Protein is a Target of 5′-l Fuligocandin B and Enhances TRAIL Resistance in Cancer Cells
作者:Midori A. Arai、Shota Taguchi、Kazuhiro Komatsuzaki、Kento Uchiyama、Ayaka Masuda、Mana Sampei、Mamoru Satoh、Sayaka Kado、Masami Ishibashi
DOI:10.1002/open.201600081
日期:2016.12
Fuligocandin B (2) is a novel natural product that can overcome TRAIL resistance. We synthesized enatiomerically pure fuligocandin B (2) and its derivative 5′‐I fuligocandin B (4), and found that the latter had an improved biological activity against the human gastric cancer cell line, AGS. We attached a biotin linker and photoactivatable aryl diazirine group to 5′‐I fuligocandin B (4), and employed
Fuligocandin B(2)是可以克服TRAIL抗性的新型天然产物。我们合成了对映体纯的富可视菌素B(2)及其衍生物5'-I富可视菌素B(4),发现后者对人胃癌细胞系AGS具有改善的生物活性。我们将生物素连接子和可光活化的芳基二嗪基团连接到5'-I fuligocandin B(4),并采用下拉测定法将包含AAA ATPase的含缬氨酸的蛋白(VCP / p97)鉴定为5'-I。 fuligocandin B(4)靶蛋白。siRNA抑制VCP可增强AGS细胞对TRAIL的敏感性。另外,4增强了CHOP和DR5蛋白的表达以及泛素化蛋白的整体细胞内水平。这些数据表明,由VCP抑制4引起的内质网应激会增加CHOP介导的DR5上调,从而增加TRAIL诱导的AGS细胞死亡。据我们所知,这是第一个显示VCP与癌细胞中TRAIL抵抗克服活性之间的关系的例子。